Its active ingredient, astragaloside IV, can upregulate the serum adiponectin level in diabetic nephropathy rats, activate AMPK, increase autophagy activity and reduce podocyte damage, thereby delaying diabetes. This evidence concerns the gene ADIPOQ and diabetic kidney disease.